PLN 47.8
(5.99%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -70.58 Million PLN | -111.18% |
2022 | -33.42 Million PLN | -1.37% |
2021 | -32.97 Million PLN | -151.94% |
2020 | -13.08 Million PLN | -49.81% |
2019 | -8.73 Million PLN | -97.56% |
2018 | -4.42 Million PLN | -2356.67% |
2017 | -180 Thousand PLN | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -9.44 Million PLN | 17.81% |
2024 Q2 | -9.98 Million PLN | -5.76% |
2023 Q4 | -11.48 Million PLN | 27.19% |
2023 Q1 | -13 Million PLN | -168.9% |
2023 Q3 | -15.77 Million PLN | 45.78% |
2023 FY | -70.58 Million PLN | -111.18% |
2023 Q2 | -29.09 Million PLN | -123.72% |
2022 Q2 | -9.73 Million PLN | 12.33% |
2022 FY | -33.42 Million PLN | -1.37% |
2022 Q4 | -4.83 Million PLN | 37.66% |
2022 Q3 | -7.75 Million PLN | 20.28% |
2022 Q1 | -11.09 Million PLN | -1.81% |
2021 Q2 | -7.47 Million PLN | -40.3% |
2021 Q4 | -10.9 Million PLN | -22.91% |
2021 Q3 | -8.87 Million PLN | -18.68% |
2021 FY | -32.97 Million PLN | -151.94% |
2021 Q1 | -5.32 Million PLN | -234.4% |
2020 FY | -13.08 Million PLN | -49.81% |
2020 Q3 | -6.31 Million PLN | 0.0% |
2020 Q4 | -1.59 Million PLN | 74.76% |
2019 FY | -8.73 Million PLN | -97.56% |
2018 FY | -4.42 Million PLN | -2356.67% |
2017 FY | -180 Thousand PLN | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Bioceltix S.A. | -13.68 Million PLN | -415.68% |
BIOTON S.A. | 2.27 Million PLN | 3202.593% |
Mabion S.A. | 41.26 Million PLN | 271.034% |
Molecure S.A. | -18.3 Million PLN | -285.532% |
NanoGroup S.A. | -7.88 Million PLN | -794.621% |
Pharmena S.A. | 28.94 Million PLN | 343.889% |
Poltreg S.A. | -13.55 Million PLN | -420.877% |
Pure Biologics Spólka Akcyjna | -35.69 Million PLN | -97.748% |
Ryvu Therapeutics S.A. | -92.11 Million PLN | 23.372% |
Synthaverse S.A. | 4.75 Million PLN | 1583.48% |
Urteste S.A. | -5.58 Million PLN | -1163.588% |